Prestige Consumer Healthcare Inc. $PBH Shares Purchased by Seizert Capital Partners LLC

Seizert Capital Partners LLC boosted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 19.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,620 shares of the company’s stock after acquiring an additional 11,224 shares during the quarter. Seizert Capital Partners LLC’s holdings in Prestige Consumer Healthcare were worth $4,282,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC increased its position in shares of Prestige Consumer Healthcare by 4.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after acquiring an additional 70,376 shares during the last quarter. Geode Capital Management LLC increased its holdings in Prestige Consumer Healthcare by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after purchasing an additional 9,455 shares during the last quarter. Congress Asset Management Co. raised its position in Prestige Consumer Healthcare by 1.8% in the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock valued at $80,616,000 after purchasing an additional 18,015 shares during the period. Westwood Holdings Group Inc. lifted its stake in Prestige Consumer Healthcare by 2.4% during the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock worth $70,420,000 after purchasing an additional 20,626 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Prestige Consumer Healthcare by 19.1% during the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after buying an additional 115,459 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $65.07 on Tuesday. The stock’s 50-day moving average is $61.51 and its two-hundred day moving average is $65.02. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70. Prestige Consumer Healthcare Inc. has a 1 year low of $57.25 and a 1 year high of $90.04. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of 16.15, a PEG ratio of 2.04 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The business’s revenue was down 3.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analyst Ratings Changes

PBH has been the subject of a number of research reports. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective on the stock in a research report on Wednesday, September 24th. Jefferies Financial Group decreased their target price on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a report on Monday, October 27th. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Canaccord Genuity Group reduced their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $85.33.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the transaction, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).